Exelixis Inc. (EXEL) exhibits 96.0% gross margins and 35.1% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 18.4x enterprise multiple and 6.8% implied options volatility.
Sustained 96.0% gross profitability converts into 37.6% operating margin and 35.1% ROIC, outpacing sector cost of capital.
ROIC: 35.1% // GM: 96.0%YoY revenue trajectory of +7.0% paired with 5.34% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +7.0% // FCF YLD: 5.34%Altman Z-Score of 16.64 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 16.64 // F-SCORE: 9/9Trading at 21.0x trailing P/E (19.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 21.0x // EV/EBITDA: 18.4xOptions market prices a ±6.8% implied move with a 0.85 put/call ratio around $65.00 max pain.
IMPL MOVE: ±6.8% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 33.7% net margins.
NET MARGIN: 33.7% // D/E: 0.13x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for EXEL & activate live FRED threshold breach alerts.